|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Usefulness of Topical Interferon Alpha-2b Eye Drop as an Adjunctive Therapy Following Surgical Resection in Ocular Surface Squamous Neoplasia.
|
31662558 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A 64-year-old Caucasian man had been diagnosed with presumed ocular surface squamous neoplasia in the left eye and started on topical interferon alpha 2b drops.
|
30849427 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Role of topical interferon alpha-2b in 'mitomycin-C-resistant' ocular surface squamous neoplasia: our preliminary findings.
|
29362973 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Presumed squamous neoplasia was treated with topical interferon α2b.
|
29023238 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PurposeTo share our initial experience in the use of intralesional interferon alpha-2a at primary presentation in ocular surface tumours as a method of immunoreduction prior to definitive surgical management.MethodsCase series of patients referred to Sheffield Ocular Oncology Service with rapidly growing ocular surface tumours, treated with intralesional interferon alpha-2a at first presentation prior to definitive surgical management.ResultsAll three patients, two with conjunctival melanoma and one with ocular surface squamous neoplasia (OSSN) demonstrated immunoreduction of tumour without any adverse side effects.ConclusionsInterferon alpha-2a is effective in conjunctival melanoma and OSSN.
|
28937145 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer.
|
28405526 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The hIFNα-2b gene was amplified from breast cancer tumor tissue samples (N = 60) by polymerase chain reaction (PCR) and the products were subjected to gene sequencing.
|
27403569 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Previously studies have shown that tumor-homing peptide NGR enhances the therapeutic efficacy of human interferon α2a (IFNα2a) against tumors.
|
21338646 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Apoptosis of tumor cells in nude mice was detected by TUNEL assay after treatment with IFN-alpha-2b.
|
19058305 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Loss of heterozygosity (LOH) assays for three microsatellite polymorphic markers on chromosome 9p21 (IFNA and D9S171), regions of putative tumor suppressor gene p16, and on chromosome 17p13 (TP53), the p53 tumor suppressor gene locus, were done.
|
16166427 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To search for genetic changes in SP, a microdissection-based genetic analysis using polymorphic markers at 9q22 (PTCH; D9S15, D9S303, D9S287, D9S252) as well as markers at 9p21 flanking the tumor suppressor gene p16 (IFNA, D9S171) was performed.
|
11285401 |
2001 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Comparison of these results with those obtained in a previous paper using flanking markers (D9S171, D9S942, D9S958 and IFNA) allowed us to detect two new cases of microsatellite instability (L-446 and L-442), and to confirm the occurrence of LOH at the INK4a/ARF locus in one tumor (M-3770).
|
10374887 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
One of the novel regions was on 9p22, where a tumor suppressor gene, interferon a cluster (IFNA) gene, was identified before.
|
10226521 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
She is currently maintained on interferon-alpha 2B but her measured vital capacity continues to fall slowly, reflecting increased tumor growth.
|
9856686 |
1998 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We analyzed 19 samples of various astrocytic tumors (3 astrocytomas, 5 anaplastic astrocytomas, and 11 glioblastomas) for loss of heterozygosity (LOH) on chromosome 9p at 6 microsatellite loci (D9S54, IFNA, D9S171, D9S104, D9S165, and D9S166).
|
8864999 |
1996 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Loss of heterozygosity (LOH) at the IFNA locus was detected in 1 of 19 (5%) tumors, but no change at the D9S171 locus was observed in 17 tumors.
|
8980248 |
1996 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, these data suggest that another tumor suppressor gene on 9p (near the IFNA locus) may contribute to the progression of differentiated adenocarcinoma of the stomach.
|
7775254 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The data presented here indicate that allelic loss from 9p21-p22 is a common occurrence in MM and further delineate the location of a putative 9p tumor suppressor gene(s) to a region between IFNA/IFNW and D9S171.
|
8402655 |
1993 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IFN-alpha 2 b salvaged 8 of 18 patients who failed with the theraccine, regardless of MHC phenotype, perhaps through upregulation of MHC and tumor epitopes on the autochthonous tumor.
|
8368734 |
1993 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Multipoint linkage analysis was performed between the familial melanoma susceptibility locus (MLM) and two short tandem repeat markers, D9S126 and the interferon-alpha (IFNA) gene, which reside in the region of somatic loss in melanoma tumors.
|
1439824 |
1992 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Results from Northern blot analysis showed that the enhanced expression of EGF-R on the A549 nodule cells treated with IFN-beta correlates with an increase in mRNA for EGF-R. No modification of the EGF-R mRNA expression was observed in nodules treated with IFN-alpha 2 or IFN-gamma.
|
2115198 |
1990 |